Becton, Dickinson and Company (NYSE:BDX) Shares Sold by OLD National Bancorp IN

OLD National Bancorp IN trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 7.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,736 shares of the medical instruments supplier’s stock after selling 303 shares during the quarter. OLD National Bancorp IN’s holdings in Becton, Dickinson and Company were worth $911,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after buying an additional 516,427 shares during the last quarter. Morgan Stanley boosted its holdings in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after buying an additional 435,168 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 11.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after buying an additional 512,566 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Becton, Dickinson and Company by 10.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 4,034,523 shares of the medical instruments supplier’s stock worth $1,043,045,000 after purchasing an additional 395,657 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Becton, Dickinson and Company by 9.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock worth $938,593,000 after purchasing an additional 304,629 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. Raymond James boosted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays boosted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $280.00.

Becton, Dickinson and Company Stock Up 0.2 %

BDX stock opened at $234.36 on Wednesday. The firm has a market cap of $67.71 billion, a PE ratio of 55.54, a PEG ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm’s 50 day moving average price is $239.72 and its 200-day moving average price is $241.79. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.98 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Insider Activity

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.